文献速递临床微生物分子诊断

基于全基因组测序数据预测肺炎链球菌抗菌药物敏感性:两种基因组工具与常规药敏试验的直接比较

Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing.
PubMed 文献 · J Clin Microbiol · 2024-12-31

本研究用538株肺炎链球菌比较Pathogenwatch和AREScloud两种全基因组测序分析工具与EUCAST表型药敏试验的预测性能。β-内酰胺类抗生素的分类一致率均>94%,但复方磺胺甲噁唑一致率<86%,红霉素和四环素在Pathogenwatch中极重大错误率较高。

要点

  • β-内酰胺类预测分类一致率高(>94%),重大错误和极重大错误率低(<1%)。
  • 红霉素和四环素AREScloud一致率>93%,Pathogenwatch约88%;复方磺胺甲噁唑两者均<86%。
  • Pathogenwatch对红霉素和四环素的极重大错误率分别为53.6%和47.0%,AREScloud为14.3%和19.1%。

核心结论

  • 两种工具对肺炎链球菌β-内酰胺类耐药预测表现优异,但非β-内酰胺类需进一步优化和验证。

研究设计与样本

  • 共纳入538株肺炎链球菌,所有菌株做纸片扩散法,β-内酰胺敏感性降低者做肉汤微量稀释法。
  • 使用Illumina全基因组测序FASTQ文件作为两种NGS工具输入,计算分类一致率、重大错误率和极重大错误率。

主要发现

  • β-内酰胺类抗生素分类一致率>94%,重大错误和极重大错误率均<1%。
  • 红霉素和四环素AREScloud分类一致率>93%,Pathogenwatch约88%;复方磺胺甲噁唑两者均<86%。
  • 红霉素和四环素极重大错误率Pathogenwatch分别为53.6%和47.0%,AREScloud分别为14.3%和19.1%。

关键数值与推荐

  • 分类一致率:β-内酰胺类>94%;红霉素和四环素AREScloud>93%、Pathogenwatch约88%;复方磺胺甲噁唑<86%。
  • 极重大错误率:红霉素Pathogenwatch 53.6%、AREScloud 14.3%;四环素Pathogenwatch 47.0%、AREScloud 19.1%。

临床怎么用

  • 全基因组测序工具可用于肺炎链球菌β-内酰胺类耐药预测,但非β-内酰胺类预测结果需谨慎解读。

局限性

  • 仅评估了两种NGS工具,未涵盖其他预测工具。
  • 非β-内酰胺类观察到高(极)重大错误率,需进一步优化和验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Determination of antimicrobial resistance (AMR) in pneumococcal isolates is important for surveillance purposes and in a clinical context. Antimicrobial susceptibility testing (AST) of pneumococci is complicated by the need for exact minimal inhibitory concentrations (MICs) of beta-lactam antibiotics. Two next-generation sequencing (NGS) analysis tools have implemented the prediction of AMR in their analysis workflow, including the prediction of MICs: Pathogenwatch (https://pathogen.watch/) and AREScloud (OpGen). The performance of these tools in comparison to phenotypic AST following EUCAST guidelines is unknown. A total of 538 Streptococcus pneumoniae isolates were used to compare both tools with phenotypic AST for penicillin, amoxicillin, cefotaxime/ceftriaxone, erythromycin, trimethoprim-sulfamethoxazole, and tetracycline. Disk diffusion was performed for all isolates, and broth microdilution was performed for isolates with reduced beta-lactam susceptibility. Demultiplexed FASTQ files from Illumina sequencing, covering the whole genome of pneumococci, were used as input for the NGS tools. Categorical agreement (CA), major error (ME), and very major error (VME) rates were calculated. For beta-lactam antibiotics, CA was high (>94%) associated with none or only one ME and VME (<1%). For erythromycin and tetracycline, CA was >93% for predictions by AREScloud, while for Pathogenwatch, this ranged around 88%. For trimethoprim-sulfamethoxazole, CA was for both tools <86%. High VME rates were observed for erythromycin and tetracycline, higher for Pathogenwatch (53.6% and 47.0%, respectively) compared to AREScloud (14.3% and 19.1%, respectively). Both tools performed excellently despite the complexity of predicting beta-lactam resistance in pneumococci. Further optimization and validation are needed for non-beta-lactams since high (very) major error rates were observed.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Sanchez GJ, Cuypers L, Laenen L, et al. Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing. J Clin Microbiol. 2024. PMID: 39745445. doi:10.1128/jcm.01079-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。